Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?

Is TEVA a bully banal to buy? We came crossed a bullish thesis on Teva Pharmaceutical Industries Limited connected Kontra Investments’s Substack by Kontra. In this article, we volition summarize the bulls’ thesis connected TEVA. Teva Pharmaceutical Industries Limited's stock was trading astatine $31.21 arsenic of April 23^rd. TEVA’s trailing and guardant P/E were 25.79 and 11.49 respectively according to Yahoo Finance.

Pressmaster/Shutterstock.com

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and different medicines, and biopharmaceutical products successful the United States and internationally. TEVA is advancing a compelling translation into a branded biopharma innovator, anchored by duvakitug (TEV-48574), a TL1A-targeting monoclonal antibody that is emerging arsenic a imaginable best-in-class therapy successful inflammatory bowel illness (IBD).

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The drug’s differentiated mechanism—blocking pro-inflammatory TL1A-DR3 signaling portion preserving the DcR3 decoy pathway—enables a much balanced immune response, which is present translating into superior objective outcomes.

In Phase 2b attraction data, duvakitug demonstrated industry-leading efficacy, with 58% objective remission successful ulcerative colitis and 55% endoscopic effect successful Crohn’s illness astatine the highest dose, outperforming competing TL1A therapies and comparing favorably adjacent against established biologics. Importantly, these results were achieved with convenient monthly dosing and a cleanable information profile, including debased immunogenicity rates of 3–5%, reinforcing its suitability arsenic a semipermanent attraction therapy.

Beyond efficacy, Teva’s broader strategical repositioning strengthens the concern case. Strong currency travel from branded assets similar Austedo is backing late-stage development, portion its 50/50 concern with Sanofi reduces fiscal risk. Duvakitug itself represents a “pipeline successful a molecule,” with enlargement opportunities crossed aggregate inflammatory diseases, importantly expanding its full addressable market.

Despite this, the marketplace continues to undervalue Teva, assigning minimal recognition to a imaginable $2.7B–$5.0B highest income asset. As Teva executes connected borderline expansion, indebtedness simplification toward ~2x EBITDA, and sustained net growth, valuation multiples are poised to re-rate meaningfully, supporting an intrinsic worth of $58–60 implicit the mean word with important upside potential.

Previously, we covered a bullish thesis connected Teva Pharmaceutical Industries Limited (TEVA) by Kontra successful April 2025, which highlighted the company’s borderline expansion, indebtedness reduction, and maturation driven by branded drugs and pipeline catalysts. TEVA’s banal terms has appreciated by astir 123.88% since our coverage. Kontra shares a akin presumption but emphasizes connected duvakitug’s best-in-class objective information and its imaginable to thrust further valuation upside.